AMSA2020: A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly patients with acute myeloid leukemia in first remission”
Phase 1
- Conditions
- elderly patients (> = 60 years) with Acute Myeloid LeukemiaTherapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]MedDRA version: 21.1Level: PTClassification code: 10000880Term: Acute myeloid leukaemia Class: 100000004864
- Registration Number
- CTIS2022-502392-37-00
- Lead Sponsor
- French Innovative Leukemia Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method